Biotech | September 03, 2021
Omeza Collegen Matrix gets U.S. FDA approval
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
The Stasis connected care monitoring system includes - a bedside monitor that monitors 6 vital signs, a tablet that enables intuitive monitoring, and the Stasis app that allows for remote monitoring across devices
The drug is also intended for the treatment of glioblastoma multiforme
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
The Evolut FX TAVR system is used for treatment of symptomatic severe aortic stenosis and it has features that enhance ease-of-use and predictable valve deployment
The company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures
Subscribe To Our Newsletter & Stay Updated
